
On Thursday, ALK-Abelló CEO Carsten Hellman could present a Q1 report that beat analysts’ growth predictions for the allergy firm’s revenue and operating profit.
”It’s nice to see that we have built a growth foundation in ALK, especially considering that the world is relatively turbulent right now. The year’s first quarter is our biggest during the year, and we delivered 13% reported growth and 11% in organic growth. It’s actually the best ever quarter in the company’s history, and the second-best operating result we’ve had,” Hellmann tells MedWatch.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app